Advanced Continuous Glucose Monitoring and Personalized Dosing of Insulin for Type 1 Diabetes with Que Dallara Medtronic

Published: July 26, 2023, 8:04 p.m.

Que Dallara, Executive Vice President and President of the Diabetes Operating Unit at Medtronic, is enthusiastic about the MiniMed 780G system, a recently FDA approved solution for people with type 1 diabetes. This system has a continuous glucose monitor, insulin pump, and mobile app that connects with CareLink, which allows the physician and family members to follow the patient as well.  This automated insulin delivery eliminates the need to count carbs and calibrates to each individual's eating habits for more accurate dosing.

 Que explains, "It's the first of its kind that has automated adjustments and corrections to insulin delivery without needing the patient to do anything. The existing systems on the market have automated basal delivery, which helps to some degree, but we've introduced this concept of meal detection technology. It can figure out that you're having a meal. For example, if you're undercounting your carbs, it can notice that you're actually having a meal and then provide order corrections so that you don't go too high. It can do that in a safe way without increasing the risk of hypoglycemia."

"So it's very difficult with a CGM alone and with just the patient to make all these decisions throughout the day. What the MiniMed 780G does is automates all of that. There's a CGM, and with the specific algorithm that we have on the 780G. It knows when you're going low, when you're going high, how much insulin on board, the rate of change of all of this, when you might have under-counted carbs, when you may have missed a bolus. And it helps you make the decision automatically. You don't have to be involved. It's truly a hands-off system."

@Medtronic #MiniMed780G #Diabetes #Type1Diabete #TypeOneDiabetes #CGM #ContinuousGlucoseMonitoring #MealDetection 

medtronicdiabetes.com

Download the transcript here

Medtronic